Atara Biotherapeutics (ATRA) shares were down almost 10% Tuesday after its active investigational new drug applications were placed on clinical hold by the US Food and Drug Administration.
The INDs cover Ebvallo, a treatment for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease, and the ATA3219 drug product for non-Hodgkin's lymphoma and systemic lupus erythematosus, the company said.
The clinical hold for both programs comes amid "compliance issues" at a third-party manufacturing facility, Atara said.
Atara said new patient recruitment for both programs have been suspended while participants in the clinical trials with potential clinical benefit may continue receiving treatment according to established study protocols.
Price: 5.95, Change: -0.63, Percent Change: -9.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.